Structure and biology of complement protein C3, a connecting link between innate and acquired immunity

Immunological Reviews

Volumn 180, Issue , 2001, Pages 35-48

  Sahu, Arvind ^a   Lambris, John D ^b  

^a NATIONAL CENTRE FOR CELL SCIENCE   (India)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COMPLEMENT COMPONENT C3;

COMPLEMENT ACTIVATION; HUMAN; IMMUNE RESPONSE; INFECTION; PHAGOCYTOSIS; PRIORITY JOURNAL; REVIEW;

AMIDES; AMINO ACID SEQUENCE; ANIMALS; AUTOIMMUNITY; COMPLEMENT ACTIVATION; COMPLEMENT C3; COMPLEMENT INACTIVATOR PROTEINS; CONSENSUS SEQUENCE; ESTERS; EVOLUTION, MOLECULAR; GRAFT REJECTION; HUMANS; IMMUNE SYSTEM; LIGANDS; MOLECULAR SEQUENCE DATA; PHAGOCYTOSIS; PROTEIN BINDING; PROTEIN CONFORMATION; SEQUENCE ALIGNMENT; SEQUENCE HOMOLOGY, AMINO ACID; STRUCTURE-ACTIVITY RELATIONSHIP; VIRUSES;

EID: 0035006284     PISSN: 01052896     EISSN: None     Source Type: Journal    
DOI: 10.1034/j.1600-065X.2001.1800103.x     Document Type: Review

References (120)

1. 1. Lambris JD, Sahu A, Wetsel R. The chemistry and biology of C3,C4, and C5. In: Volanakis JE, Frank M, eds. The human complement system in health and disease. New York: Marcel Dekker Inc; 1998. p. 83-118.
2. 2. Al-Sharif WZ, Sunyer JO, Lambris JD, Smith LC. Sea urchin coelomocytes specifically express a homologue of the complement component C3. J Immunol 1997;160:2983-2997.
3. 3. Nonaka M, Phylogeny of the complement system. In: Volanakis JE, Frank MM, eds. The human complement system in health and disease. New York: Marcel Dekker Inc; 1998. p. 203-215.
4. 1,4,2 to E* Science 1958;127:234-236.
5. 5. Pepys MB. Role of complement in induction of antibody production in vivo. Effect of cobra factor and other C3-reactive agents on thymus-dependent and thymus-independent antibody responses. J Exp Med 1974;140:126-145.
6. 6. Whitehead AS, Solomon E, Chambers S, Bodmer WF, Povey S, Fey G. Assignment of the structural gene for the third component of complement to chromosome 19. Proc Natl Acad Sci USA 1982;79:5021-5025.
7. 7. De Bruijn MHL, Fey GH. Human complement component C3: cDNA coding sequence and derived primary structure. Proc Natl Acad Sci USA 1985;82:708-712.
8. 8. Misumi Y, Oda K, Fujiwara T, Takami N, Tashiro K, Ikehara Y. Functional expression of furin demonstrating its intracellular localization and endoprotease activity for processing of proalbumin and complement pro-C3. J Biol Chem 1991;266:16954-16959.
9. 9. Hase S, Kikuchi N, Ikenaka T, Inoue K. Structures of sugar chains of the third component of human complement. J Biochem (Tokyo) 1985;98:863-874.
10. 10. Hirani S, Lambris JD, Müller-Eberhard HJ. Structural analysis of the asparagine-linked oligosaccharides of human complement component C3. Biochem J 1986;233:613-616.
11. 11. Huber R, Scholze H, Paques EP, Deisenhofer J. Crystal structure analysis and molecular model of human C3a anaphylatoxin. Hoppe Seylers Z Physiol Chem 1980;361:1389-1399.
12. 12. Dolmer K, Sottrup-Jensen L. Bisulfide bridges in human complement component C3b. FEBS Lett 1993;315:85-90.
13. 13. Nagar B, Jones RG, Diefenbach RJ, Isenman DE, Rini JM. X-ray crystal structure of C3d: a C3 fragment and ligand for complement receptor 2. Science 1998;280:1277-1281.
14. 14. Dolmer K, Thirup S, Andersen GR, Sottrup-Jensen L, Nyborg J. Crystallization of human methylamine-treated complement C3 and C3b. Acta Crystallogr 1994;D50:786-789.
15. 15. Müller-Eberhard HJ, Dalmasso AP, Calcott MA. The reaction mechanism of β1c-Globulin (C′3) in immune hemolysis. J Exp Med 1966;123:33-54.
16. 16. Law SKA, Dodds AW. The internal thioester and the covalent binding properties of the complement proteins C3 and C4. Protein Sci 1997;6:263-274.
17. 17. Tack BF, Harrison RA, Janatova J, Thomas ML, Prahl JW. Evidence for presence of an internal thiolester bond in third component of human complement. Proc Natl Acad Sci USA 1980;77:5764-5768.
18. 18. Fong KY, Botto M, Walport MJ, So AK. Genomic organization of human complement component C3. Genomics 1990;7:579-586.
19. 19. Pangburn MK, Schreiber RD, Müller-Eberhard HJ. Formation of the initial C3 convertase of the alternative pathway: acquisition of C3b-like activities by spontaneous hydrolysis of the putative thioester in native C3. J Exp Med 1981;154:856-867.
20. 20. Hack CE, Paardekooper J, Van Milligen F. Demonstration in human plasma of a form of C3 that has the conformation of "C3b-like C3". J Immunol 1990;144:4249-4255.
21. 21. Sahu A, Kozel TR, Pangburn MK. Specificity of the thioester-containing reactive site of human C3 and its significance to complement activation. Biochem J 1994;302:429-436.
22. 22. Sahu A, Pangburn MK. Covalent attachment of human complement C3 to IgG: identification of the amino acid residue involved in ester linkage formation. J Biol Chem 1994;269:28997-29002.
23. 23. Sahu A, Pangburn MK. Tyrosine is a potential site for covalent attachment of activated complement component C3. Mol Immunol 1995;32:711-716.
24. 24. Sahu A, Pangburn MK. Investigation of mechanism-based inhibitors of complement targeting the activated thioester of human C3. Biochem Pharmacol 1996;51:797-804.
25. 25. Kim YU, et al. Covalent binding of C3b to C4b within the classical complement pathway C5 convertase: determination of amino acid residues involved in ester linkage formation. J Biol Chem 1992;267:4171-4176.
26. 26. Kinoshita T, Takata Y, Kozono H, Takeda J, Hong K, Inoue K. C5 convertase of the alternative complement pathway: covalent linkage between two C3b molecules within the trimolecular complex enzyme. J Immunol 1988;141:3895-3901.
27. 27. Carroll MC. The role of complement and complement receptors in induction and regulation of immunity. Annu Rev Immunol 1998;16:545-568.
28. 28. Lambris JD. The multifunctional role of C3, the third component of complement. Immunol Today 1988;9:387-393.
29. 29. Lambris JD, Lao Z, Oglesby TJ, Atkinson JP, Hack E, Becherer JD. Dissection of CR1, factor H, MCP, and factor B binding and functional sites in third complement component. J Immunol 1996;156:4821-4832.
30. 30. Ross GD, Lambris JD, Cain JA, Newman SL. Generation of three different fragments of bound C3 with purified factor I or serum. I. Requirements for factor H vs CR1 cofactor activity. J Immunol 1982;129:2051-2060.
31. 31. Medicus RG, Melamed J, Arnaout MA. Role of human factor I and C3b receptor in the cleavage of surface-bound C3b. Eur J Immunol 1983;13:465-470.
32. 32. Davis AEI, Harrison RA. Structural characterization of factor I mediated cleavage of the third component of complement. Biochemistry 1982;21:5745-5749.
33. 1 inactivates the alternative complement pathway. J Immunol 1998;160:5596-5604.
34. 34. Nilsson B, Grossberger D, Nilsson Ekdahl K, Riegert P, Becherer D, Lambris JD. Conformational differences between surface-bound and fluid-phase complement-component-C3 fragments. Epitope mapping by cDNA expression. Biochem J 1992;282:715-721.
35. 35. Low PJ, Ai R, Ogata RT. Active sites in complement components C5 and C3 identified by proximity to indels in the C3/4/5 protein family. J Immunol 1999;162:6580-6588.
36. 36. Ogata RT, Ai R, Low PJ. Active sites in complement component C3 mapped by mutations at indels. J Immunol 1998;161:4785-4794.
37. 37. Daoudaki ME, Becherer JD, Lambris JD. A 34-amino acid peptide of the third component of complement mediates properdin binding [published erratum appears in J Immunol 1988;141:1788]. J Immunol 1988;140:1577-1580.
38. 38. Hirani S, Lambris JD, Müller-Eberhard HJ. Localization of the conglutinin binding site on the third component of human complement. J Immunol 1985;134:1105-1109.
39. 39. Lambris JD, Avila D, Becherer JD, Müller-Eberhard HJ. A discontinuous factor H binding site in the third component of complement as delineated by synthetic peptides. J Biol Chem 1988;263:12147-12150.
40. 40. Becherer JD, Lambris JD. Identification of the C3b receptor-binding domain in third component of complement. J Biol Chem 1988;263:14586-14591.
41. 41. Lambris JD, Ganu VS, Hirani S, Müller-Eberhard HJ. Mapping of the C3d receptor (CR2)-binding site and a neoantigenic site in the C3d domain of the third component of complement. Proc Natl Acad Sci USA 1985;82:4235-1239.
42. 42. Chapitis J, Lepow IH. Multiple sedimenting species of properdin in human and interaction of purified properdin with the third component of complement. J Exp Med 1976;143:241-257.
43. 43. Lambris JD, Alsenz J, Schulz TF, Dierich MP. Mapping of the properdin-binding site in the third component of complement. Biochem J 1984;217:323-326.
44. 44. Braconier JH, Sjoholm AG, Soderstrom C. Fulminant meningococcal infections in a family with inherited deficiency of properdin. Scand J Infect Dis 1983;15:339-344.
45. 45. Fishelson Z. Complement-C3 - a molecular mosaic of binding sites. Mol Immunol 1991;28:545-552.
46. 46. Taniguchi-Sidle A, Isenman DE. Interactions of human complement component C3 with factor B and with complement receptors type 1 (CR1, CD35) and type 3 (CR3, CD11b/CD18) involve an acidic sequence at the N-terminus of C3 α-chain. J Immunol 1994;153:5285-5302.
47. 47. Jokiranta TS, Hellwage J, Koistinen V, Zipfel PF, Meri S. Each of the three binding sites on complement factor H interacts with a distinct site on C3b. J Biol Chem 2000;275:27657-27662.
48. 48. Oran AE, Isenman DE. Identification of residues within the 727-767 segment of human complement component C3 important for its interaction with factor H and with complement receptor 1 (CR1, CD35). J Biol Chem 1999;274:5120-5130.
49. 49. Ross GD, Polley MJ. Specificity of human lymphocyte complement receptors. J Exp Med 1975;141:1163-1180.
50. 50. Reynes M, et al. Human follicular dendritic cells express CR1, CR2, and CR3 complement receptor antigens. J Immunol 1985;135:2687-2694.
51. 51. Fischer E, Delibrias C, Kazatchkine MD. Expression of CR2 (the C3dg/EBV receptor, CD21) on normal human peripheral blood T lymphocytes. J Immunol 1991;146:865-869.
52. 52. Fischer MB, et al. Regulation of the B cell response to T-dependent antigens by classical pathway complement. J Immunol 1996;157:549-556.
53. 53. Ahearn JM, et al. Disruption of the Cr2 locus results in a reduction in B-1a cells and in an impaired B cell response to T-dependent antigen. Immunity 1996;4:251-262.
54. 54. Molina H, et al. Markedly impaired humoral immune response in mice deficient in complement receptors 1 and 2. Proc Natl Acad Sci USA 1996;93:3357-3361.
55. 55. Heyman B, Wiersma EJ, Kinoshita T. In vivo inhibition of the antibody response by a complement receptor-specific monoclonal antibody. J Exp Med 1990;172:665-668.
56. 56. Hebell T, Ahearn JM, Fearon DT. Suppression of the immune response by a soluble complement receptor of B lymphocytes. Science 1991;254:102-105.
57. 57. Kinoshita T, et al. Characterization of murine complement receptor type 2 and its immunological cross-reactivity with type 1 receptor. Int Immunol 1990;2:651-659.
58. 58. Dempsey PW, Allison MED, Akkaraju S, Goodnow CC, Fearon DT. C3d of complement as a molecular adjuvant: bridging innate and acquired immunity. Science 1996;271:348-350.
59. 59. Lou D, Kohler H. Enhanced molecular mimicry of CEA using photoaffinity crosslinked C3d peptide. Nat Biotechnol 1998;16:458-462.
60. 60. Ross TM, Bright RA, Robinson HL. C3d enhancement of antibodies to hemagglutinin accelerates protection against influenza virus. Nat Immunol 2000;1:127-131.
61. 61. Tanner J, Whang Y, Sample J, Sears A, Kieff E. Soluble gp350/220 and deletion mutant glycoprotein block Epstein-Barr virus adsorption to lymphocytes. J Virol 1988;62:4452-4464.
62. 62. Diefenbach RJ, Isenman DE. Mutation of residues in the C3dg region of human complement component C3 corresponding to a proposed binding site for complement receptor type 2 (CR2, CD21) does not abolish binding of iC3b or C3dg to CR2. J Immunol 1995;154:2303-2320.
63. 63. Irani VR, Lambris JD. Studies on the interaction of C3dg with CR2. FASEB J 1999;13:A282-A282.
64. 64. Clemenza L, Isenman DE. Structure-guided identification of C3d residues essential for its binding to complement receptor 2 (CD21). J Immunol 2000;165:3839-3848.
65. 65. Vik DP, et al. Structural features of the human C3-gene - intron/exon organization, transcriptional start site, and promoter region sequence. Biochemistry 1991;30:1080-1085.
66. 66. Carney DF, Haviland DL, Noack D, Wetsel RA, Vik DP, Tack BF. Structural aspects of the human C5-gene - intron/exon organization, 5′-flanking region features, and characterization of two truncated cDNA clones. J Biol Chem 1991;266:18786-18791.
67. 67. Ogata RT, Rosa PA, Zepf NE. Sequence of the gene for murine complement component C4. J Biol Chem 1989;264:16565-16572.
68. 68. Sunyer JO, Zarkadis IK, Lambris JD. Complement diversity: a mechanism for generating immune diversity? Immunol Today 1998;19:519-523.
69. z-macroglobulin family. J Immunol 1995;154:2164-2174.
70. 70. Lambris JD, et al. The third component of Xenopus complement. cDNA cloning, structural and functional analysis, and evidence for an alternate C3 transcript. Eur J Immunol 1995;25:572-578.
71. 71. Zarkadis IK, Sarrias MR, Sfyroera G, Sunyer JO, Lambris JD. Cloning and structure of three rainbow trout C3 molecules: a plausible explanation for their functional diversity. Dev Comp Immunol 2001;25:11-24.
72. 72. Sunyer JO, Zarkadis IK, Sahu A, Lambris JD. Multiple forms of complement C3 in trout, that differ in binding to complement activators. Proc Natl Acad Sci USA 1996;93:8546-8551.
73. 73. Nonaka M, Irie M, Tanabe K, Kaidoh T, Natsuume-Sakai S, Takahashi M. Identification and characterization of a variant of the third component of complement (C3) in rainbow trout (Salmo gairdneri) serum. J Biol Chem 1985;260:809-814.
74. 74. Nakao K, Obo R, Mutsuro J, Yano T. Sequence diversity of cDNA encoding the third component (C3) of carp (Cyprinus carpio). Dev Comp Immunol 1997;21:144.
75. 75. Sunyer JO, Zarkadis I, Sarrias MR, Hansen JD, Lambris JD. Cloning, structure, and function of two rainbow trout Bf molecules. J Immunol 1998;161:4106-4114.
76. 76. Sunyer JO, Tort L, Lambris JD. Structural C3 diversity in fish - characterization of five forms of C3 in the diploid fish Sparus aurata. J Immunol 1997;158:2813-2821.
77. 77. Isenman DE, Young JR. The molecular basis for the difference in immune hemolysis activity of the Chido and Rodgers isotypes of human complement component C4. J Immunol 1984;132:3019-3027.
78. 78. Law SKA, Dodds AW, Porter RR. A comparison of the properties of two classes, C4A and C4B, of the human complement component C4. EMBO J 1984;3:1819-1823.
79. 79. Gadjeva M, Dodds AW, Taniguchi-Sidle A, Willis AC, Isenman DE, Law SK. The covalent binding reaction of complement component C3. J Immunol 1998;161:985-990.
80. 80. Saha K, Dash K, Sahu A, Antibody dependent haemolysin, complement and opsonin in sera of a major carp, Cirrhina mrigala and catfish, Clarias batrachus and Heteropneustes fossilis. Comp Immunol Microbiol Infect Dis 1993;16:323-330.
81. 81. Sahu A, Sunyer JO, Moore WT, Sarrias MR, Soulika AM, Lambris JD. Structure, functions, and evolution of the third complement component and viral molecular mimicry. Immunol Res 1998;17:109-121.
82. 82. Kotwal GJ, Moss B. Vaccinia virus encodes a secretory polypeptide structurally related to complement control proteins. Nature 1988;335:176-178.
83. 83. Kotwal GJ, Isaacs SN, Mckenzie R, Frank MM, Moss B. Inhibition of the complement cascade by the major secretory protein of vaccinia virus. Science 1990;250:827-830.
84. 84. Isaacs SN, Kotwal GJ, Moss B. Vaccinia virus complement-control protein prevents antibody-dependent complement-enhanced neutralization of infectivity and contributes to virulence. Proc Natl Acad Sci USA 1992;89:628-632.
85. 85. Mckenzie R, Kotwal GJ, Moss B, Hammer CH, Frank MM. Regulation of complement activity by vaccinia virus complement-control protein. J Infect Dis 1992;166:1245-1250.
86. 86. Vanderplasschen A, Mathew E, Hollinshead M, Sim RB, Smith GL. Extracellular enveloped vaccinia virus is resistant to complement because of incorporation of host complement control proteins into its envelope. Proc Natl Acad Sci USA 1998;95:7544-7549.
87. 87. Massung RF, et al. Potential virulence determinants in terminal regions of variola smallpox virus genome. Nature 1993;366:748-751.
88. 88. Shchelkunov SN, et al. Structural-functional organization of the smallpox virus genome. 1. Cloning of viral-DNA HINDIII and XHOI fragments and sequencing of HINDIII fragment-M, fragment-L, and fragment-I. Mol Biol 1992;26:731-744.
89. 89. Albrecht JC, Fleckenstein B. New member of the multigene family of complement control proteins in herpesvirus saimiri. J Virol 1992;66:3937-3940.
90. 90. Fodor WL, et al. The complement control protein homolog of herpesvirus saimiri regulates serum complement by inhibiting C3 convertase activity. J Virol 1995;69:3889-3892.
91. 91. Russo JJ, et al. Nucleotide sequence of the Kaposi sarcoma-associated herpesvirus (HHV8). Proc Natl Acad Sci USA 1996;93:14862-14867.
92. 92. Virgin HW, et al. Complete sequence and genomic analysis of murine gammaherpesvirus 68. J Virol 1997;71:5894-5904.
93. 93. Friedman HM, Cohen GH, Eisenberg RJ, Seidel CA, Cines DB. Glycoprotein C of herpes simplex virus 1 acts as a receptor for the C3b complement component on infected cells. Nature 1984;309:633-635.
94. 94. Spear PG, Antigenic structure of herpes simplex viruses. In: van Regenmortel MVH, Neurath AR, eds. Immunochemistry of viruses. The basis for serodiagnosis and vaccines. Amsterdam: Elsevier Science Publishers; 1985. p. 425-446.
95. 95. McNearney TA, Odell C, Holers VM, Spear PG, Atkinson JP. Herpes simplex virus glycoproteins gC-1 and gC-2 bind to the third component of complement and provide protection against complement mediated neutralization of viral infectivity. J Exp Med 1987;166:1525-1535.
96. 96. Friedman HM, et al. Immune evasion properties of herpes simplex virus type 1 glycoprotein gC. J Virol 1996;70:4253-4260.
97. 97. Johnson DC, Spear PG. O-linked oligosaccharides are acquired by herpes simplex virus glycoproteins in the Golgi apparatus. Cell 1983;32:987-997.
98. 98. Tal-Singer R, et al. Interaction of herpes simplex virus glycoprotein gC with mammalian cell surface molecules. J Virol 1995;69:4471-4483.
99. 99. Kostavasil I, Sahu A, Friedman HM, Eisenberg RJ, Cohen GH, Lambris JD. Mechanism of complement inactivation by glycoprotein C of herpes simplex virus. J Immunol 1997;158:1763-1771.
100. 100. Fries LF, Friedman HM, Cohen GH, Eisenberg RJ, Hammer CH, Frank MM. Glycoprotein C of herpes simplex virus 1 is an inhibitor of the complement cascade. J Immunol 1986;137:1636-1641.
101. 101. Hung SL, et al. The interaction of glycoprotein C of herpes simplex virus types 1 and 2 with the alternative complement pathway. Virology 1994;203:299-312.
102. 102. Lubinski J, Wang L, Mastellos D, Sahu A, Lambris JD, Friedman HM. In vivo role of complement-interacting domains of herpes simplex virus type I glycoprotein gC. J Exp Med 1999;190:1637-1646.
103. 103. Cooper NR. Complement evasion strategies of microorganisms. Immunol Today 1991;12:327-331.
104. 104. Nemerow GR, Houghten RA, Moore MD, Cooper NR. Identification of an epitope in the major envelope protein of Epstein-Barr virus that mediates viral binding to the B lymphocyte EBV receptor (CR2). Cell 1989;56:369-377.
105. 105. Molina H, et al. Analysis of Epstein-Barr virus-binding sites on complement receptor 2 (CR2/CD21) using human-mouse chimeras and peptides. At least two distinct sites are necessary for ligand-receptor interaction. J Biol Chem 1991;266:12173-12179.
106. 106. Bergelson JM, Chan M, Solomon KR, Stjohn NF, Lin HM, Finberg RW. Decay-accelerating factor (CD55), a glycosylphosphatidylinositol-anchored complement regulatory protein, is a receptor for several echoviruses. Proc Natl Acad Sci USA 1994;91:6245-6249.
107. 107. Manchester M, Liszewski MK, Atkinson JP, Oldstone MB. Multiple isoforms of CD46 (membrane cofactor protein) serve as receptors for measles virus. Proc Natl Acad Sci USA 1994;91:2161-2165.
108. 108. Lambris JD, Holers VM. Therapeutic interventions in the complement system. Totowa: Humana Press Inc; 2000.
109. 109. Sahu A, Lambris JD, Complement inhibitors: a resurgent concept in anti-inflammatory therapeutics. Immunopharmacology 2000;49:133-148.
110. 110. Sahu A, Morikis D, Lambris JD. Complement inhibitors targeting C3, C4, and, C5. In: Lambris JD, Holers VM, eds. Therapeutic interventions in the complement system. Totowa: Humana Press Inc; 2000. p. 75-112.
111. 111. Sahu A, Kay BK, Lambris JD. Inhibition of human complement by a C3-binding peptide isolated from a phage displayed random peptide library. J Immunol 1996;157:884-891.
112. 112. Furlong ST, et al. C3 activation is inhibited by analogs of compstatin but not by serine protease inhibitors or peptidyl α-ketoheterocycles. Immunopharmacology 2000;48:199-212.
113. 113. Sahu A, Soulika AM, Morikis D, Spruce L, Moore WT, Lambris JD. Binding kinetics, structure-activity relationship, and biotransformation of the complement inhibitor compstatin. J Immunol 2000;165:2491-2499.
114. 114. Fiane AE, et al. Compstatin, a peptide inhibitor of C3, prolongs survival of ex vivo perfused pig xenografts. Xenotransplantation 1999;6:52-65.
115. 115. Fiane AE, et al. Prolongation of ex vivo-perfused pig xenograft survival by the complement inhibitor compstatin. Transplant Proc 1999;31:934-935.
116. 116. Nilsson B, et al. Compstatin inhibits complement and cellular activation in whole blood in two models of extracorporeal circulation. Blood 1998;92:1661-1667.
117. 117. Soulika AM, et al. Inhibition of heparin/ protamine complex-induced complement activation by compstatin in baboons. Clin Immunol 2000;96:212-221.
118. 118. Morikis D, Assa-Munt N, Sahu A, Lambris JD. Solution structure of compstatin, a potent complement inhibitor. Protein Sci 1998;7:619-627.
119. 119. Del Rio-Tsonis K, Tsonis PA, Zarkadis IK, Tsangas AG, Lambris JD. Expression of the third component of complement, C3, in regenerating limb blastema cells of urodeles. J Immunol 1998;161:6819-6814.
120. 120. Mastellos D, Papadimitriou J, Franchini S, Tsonis PA, Lambris JD. A novel role of complement: mice deficient in the fifth component of complement (C5) exhibit impaired liver regeneration. J Immunol (In press).